Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2023–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Market Cap | $7M | $28M | — | — |
| Enterprise Value | $32M | $53M | — | — |
| P/E Ratio → | -0.04 | — | — | — |
| P/S Ratio | 0.32 | 1.22 | — | — |
| P/B Ratio | — | — | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV / Revenue | — | 2.27 | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Gross Margin | -41.3% | -41.3% | 9.7% | — |
| Operating Margin | -347.9% | -347.9% | -33.9% | — |
| Net Profit Margin | -433.9% | -433.9% | -37.8% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ROE | — | — | -357.7% | — |
| ROA | -230.7% | -230.7% | -23.8% | -855.8% |
| ROIC | -282.6% | -282.6% | -32.2% | — |
| ROCE | -813.4% | -813.4% | -73.4% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Debt / Equity | — | — | 3.73 | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | — | 3.58 | — |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | -17.73 | -17.73 | -7.25 | -191.01 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Current Ratio | 0.09 | 0.09 | 0.40 | 0.12 |
| Quick Ratio | 0.04 | 0.04 | 0.15 | 0.12 |
| Cash Ratio | 0.00 | 0.00 | 0.03 | 0.00 |
| Asset Turnover | — | 0.77 | 0.32 | — |
| Inventory Turnover | 20.11 | 20.11 | 1.72 | — |
| Days Sales Outstanding | — | 17.79 | 75.42 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $1M | $1M | $894400 |
Imminent liquidity and solvency
As reported in recent financial statements, Wellgistics Health's gross margin plummeted to negative 12.0% in 2026Q1, a stark departure from industry norms that suggests the company's core distribution activities are currently failing to cover the direct costs of inventory acquisition and fulfillment.
The persistent negative gross margin implies that the company is effectively subsidizing its customer base, likely in a desperate attempt to gain market share or drive platform adoption. This level of margin erosion is unsustainable and suggests that the current business model lacks the pricing power or operational efficiency required to achieve profitability in the competitive pharmaceutical distribution sector.
Based on the company's reported figures, the cash conversion cycle has fluctuated wildly, reaching negative 463 days in 2026Q1, which indicates significant volatility in how the firm manages its inventory and accounts payable relative to its revenue generation.
The extreme swings in the cash conversion cycle suggest that the company's working capital management is highly unstable and potentially reliant on aggressive payment terms with suppliers. Investors should monitor whether these metrics reflect genuine operational improvements or merely temporary accounting maneuvers designed to mask underlying liquidity pressures.
According to the 2026Q1 balance sheet, the company maintains a current ratio of only 0.09, a critical liquidity mismatch that leaves the firm with virtually no buffer to meet its short-term obligations without immediate and potentially dilutive external financing or capital market intervention.
A current ratio below 0.10 is exceptionally low for a distribution business that requires significant working capital to maintain inventory levels. This liquidity position suggests that the company is operating on the brink of insolvency and may be forced to seek emergency capital, which would likely be highly dilutive to existing shareholders.
As evidenced by the financial data, the company's return on invested capital has remained deeply negative, reaching negative 34.6% in 2026Q1, which highlights a consistent failure to generate a return on the capital deployed into the business over the past several quarters.
The persistent negative ROIC indicates that the company is destroying shareholder value with every dollar of capital it invests. This trend suggests that the current strategy of aggressive expansion is not creating a sustainable competitive advantage and that the firm's capital allocation warrants extreme skepticism from investors.
The market's reliance on the price-to-sales ratio for Wellgistics Health is fundamentally misapplied, as it ignores the company's negative gross margins and the fact that top-line growth is currently being achieved at the expense of long-term solvency and operational viability.
Using a P/S multiple for a company with negative gross margins is misleading because it treats all revenue as equally valuable, regardless of whether that revenue is profitable. Analysts should instead focus on the cash-burn rate and the company's ability to reach a positive gross margin, as these metrics are far more indicative of the firm's true financial health than revenue multiples.
Includes 30+ ratios · 3 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying WGRX stock.
Wellgistics Health, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Wellgistics Health, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Wellgistics Health, Inc. has -41.3% gross margin and -347.9% operating margin.